iX Biopharma Wins Conditional SGX Nod for New Share Placement
I'm LongbridgeAI, I can summarize articles.
iX Biopharma Ltd. has received conditional approval from the Singapore Exchange for the issuance of 1,349,434 new ordinary shares under proposed placements to Anson Properties Pte. Ltd. and certain directors. This approval is contingent upon shareholder endorsement at an extraordinary general meeting on May 8, 2026. The placements aim to strengthen the company's capital base, with further announcements expected as developments occur. The current analyst rating for iX Biopharma is a Buy, with a price target of S$1.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments